Genomes and Genes
Summary: Steroidal compounds related to PROGESTERONE, the major mammalian progestational hormone. Progesterone congeners include important progesterone precursors in the biosynthetic pathways, metabolites, derivatives, and synthetic steroids with progestational activities.
Publications258 found, 100 shown here
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trialJacques E Rossouw
Division of Women s Health Initiative, National Heart, Lung, and Blood Institute, 6705 Rockledge Dr, One Rockledge Ctr, Suite 300, Bethesda, MD 20817
JAMA 288:321-33. 2002..Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain...
- Different cardiovascular effects of progestins according to structure and activityA Nath
Tietze fellow from the Population Council, New York, NY, USA
Climacteric 12:96-101. 2009..Although it is likely that the new progestins may be neutral on the coronary disease risk, when administered to the younger postmenopausal woman, this has not as yet been documented by large, randomized, controlled trials...
- Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacyStefano Lello
Endocrinological Gynecology, Pathophysiology of Menopause and Osteoporosis Unit, IRCCS Istituto Dermopatico dell Immacolata, Rome, Italy
Drugs 70:541-59. 2010....
- Drospirenone in combination with estrogens: for contraception and hormone replacement therapyW H K Oelkers
Endokrinologikum, Berlin, Germany
Climacteric 8:19-27. 2005....
- Activation of nitric oxide synthesis in human endothelial cells using nomegestrol acetateTommaso Simoncini
Molecular and Cellular Gynecological Endocrinology Laboratory MCGEL, Department of Reproductive Medicine and Child Development, Division of Obstetrics and Gynecology, University of Pisa, Pisa, Italy
Obstet Gynecol 108:969-78. 2006..The aim of this study was to establish whether nomegestrol acetate induces signaling events in human endothelial cells that differ from those of other progestins, such as natural progesterone or medroxyprogesterone acetate...
- Nomegestrol acetate: steroid receptor transactivation profile in Chinese hamster ovary cells and ovulation inhibition in rat and monkeyHarry A van Diepen
Women s Health Department, Merck Research Laboratories, Oss, The Netherlands
Contraception 84:199-204. 2011..Activity of nomegestrol acetate (NOMAC), levonorgestrel (LNG), drospirenone (DRSP), dienogest (DNG) and progesterone on human steroid receptor transactivation was investigated. Ovulation inhibition by NOMAC, LNG and progesterone was tested...
- Nomegestrol acetate, a novel progestogen for oral contraceptionAlfred O Mueck
Department of Endocrinology and Menopause, University Women s Hospital, Calwer Strasse 7, DE 72076, Tubingen, Germany
Steroids 76:531-9. 2011..These clinical findings are promising; however, full publication of results from the pivotal phase III trials of NOMAC/E2 is pending...
- Nomegestrol acetate and vascular reactivity: nonhuman primate experimentsJ M Paris
Laboratoire Theramex, BP 59, 6 Avenue Prince Hereditaire Albert, 98007, Monaco
Steroids 65:621-7. 2000..In these two nonhuman primate cardiovascular models, NOMAC did not have the negating effects observed with MPA...
- Effect of nomegestrol acetate on human estrogen sulfotransferase activity in the hormone-dependent MCF-7 and T-47D breast cancer cell linesGerard Samuel Chetrite
Hormones and Cancer Research Unit, Institut de Puericulture, 26 Boulevard Brune, 75014 Paris, France
Anticancer Res 23:4651-5. 2003....
- The pharmacology of nomegestrol acetateXiangyan Ruan
Department of Gynecological Endocrinology, Beijing OB GYN Hospital, Capital Medical University, Beijing, China
Maturitas 71:345-53. 2012....
- Certain progestins prevent the enhancing effect of 17beta-estradiol on NO-mediated inhibition of platelet aggregation by endothelial cellsMurielle Zerr-Fouineau
Département de Pharmacologie et Physico Chimie, Institut Gilbert Laustriat, Université Louis Pasteur Strasbourg I, Illkirch, France
Arterioscler Thromb Vasc Biol 29:586-93. 2009..This study examined whether progestins affect the stimulatory effect of estrogens on the endothelial formation of nitric oxide (NO), a potent antithrombotic factor...
- Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimensE Lundstrom
Department of Obstetrics and Gynecology, Karolinska Hospital, Stockholm, Sweden
Climacteric 4:42-8. 2001..The aim of this study was to evaluate the impact of different hormone replacement therapy (HRT) regimens on mammographic breast density...
- [After the early termination of the Women's Health Initiative study. New American recommendations for postmenopausal hormone therapy]Martin Stjernquist
Institutionen för obstetrik och gynekologi, Malmo, Lunds universitet, Kvinnokliniken, Universitetssjukhuset MAS, Malmo
Lakartidningen 100:1790-7. 2003..Establishing an individual risk profile is essential. The author of this article also emphasizes a restrictive attitude for patients with increased risk of thromboembolic disease...
- Trace elements and vitamin levels in menopausal women receiving hormone replacement therapyI Meram
Department of Biochemistry, Medical Faculty, University of Gaziantep, Turkey
Clin Exp Obstet Gynecol 30:32-4. 2003..001). In conclusion we observed a beneficial effect of HRT on serum levels of trace elements, vitamin A, and vitamin E in addition to the well known other benefits...
- Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trialStephen R Rapp
Department of Psychiatry and Behavioral Medicine, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
JAMA 289:2663-72. 2003..On July 8, 2002, the estrogen plus progestin therapy in the WHI trial was discontinued because of certain increased health risks for women...
- Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trialSally A Shumaker
Department of Public Health Sciences, Wake Forest University Health Sciences, Winston Salem, NC 27104, USA
JAMA 289:2651-62. 2003..On July 8, 2002, the study drugs, estrogen plus progestin, in the Women's Health Initiative (WHI) trial were discontinued because of certain increased health risks in women receiving combined hormone therapy...
- A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestoneJ H Meuwissen
Diagnostisch Centrum, Eindhoven, The Netherlands
Gynecol Endocrinol 15:349-58. 2001..It was concluded that the E2 + TMG combination was either equivalent or superior to the E2V + NG combination in the treatment of hot flushes and other climacteric symptoms, and that its bleeding profile was favorable...
- The effect of medroxyprogesterone acetate and norethisterone on the estradiol stimulated proliferation in MCF-7 cells: comparison of continuous combined versus sequential combined estradiol/progestin treatmentC Lippert
Centre for Endocrinology and Menopause, Department of Obstetrics and Gynaecology, University of Tuebingen, Tuebingen, Germany
Eur J Gynaecol Oncol 22:331-5. 2001..These findings might be useful in the elucidation of potential mechanisms involved in the clinical situation...
- Contrasting effects of two hormone replacement therapies on the cardiovascular and mammary gland outcomes in surgically postmenopausal monkeysIrma H Suparto
Comparative Medicine Clinical Research Center, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
Am J Obstet Gynecol 188:1132-40. 2003....
- Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized TrialRowan T Chlebowski
Harbor UCLA Research and Education Institute, Torrance 90502, USA
JAMA 289:3243-53. 2003..Outstanding issues not previously addressed include characteristics of breast cancers observed among women using hormones and whether diagnosis may be influenced by hormone effects on mammography...
- Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal womenInci Davas
Second Obstetrics and Gynecology Clinic, Sisli Etfal Training and Research Hospital, Istanbul, Turkey
Fertil Steril 80:536-40. 2003..To evaluate the effect of daily oral and transdermal hormone therapy alone or in combination with alendronate on bone mineral density in postmenopausal women...
- Combination hormone replacement therapy and dementiaEric Wooltorton
CMAJ 169:133. 2003
- Effects of trimonthly progestin administration on the endometrium in elderly postmenopausal women who receive hormone replacement therapy: a pilot studyAnil B Pinto
Department of Obstetrics and Gynecology, Washington University School of Medicine, USA
Am J Obstet Gynecol 189:11-5. 2003..The purpose of this study was to determine the effect of trimonthly progestin administration on the endometrium in elderly postmenopausal women who receive hormone replacement therapy...
- Quantification of ovarian stromal Doppler signals in postmenopausal women receiving hormone replacement therapyHsien An Pan
Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, Tainan, Taiwan
Menopause 10:366-72. 2003..To investigate the effect of continuous-combined hormone replacement therapy (HRT) on ovarian circulation, we used three-dimensional power Doppler ultrasound to assess ovarian stromal blood flow in postmenopausal women...
- The relation of oxidized LDL autoantibodies and long-term hormone replacement therapy to ultrasonographically assessed atherosclerotic plaque quantity and severity in postmenopausal womenT A Koivu
The Research Laboratory of Atherosclerosis Genetics, Department of Clinical Chemistry, Centre for Laboratory Medicine, University Hospital of Tampere, PO Box 2000, 33521 Tampere, Finland
Atherosclerosis 157:471-9. 2001....
- Comparison of Pueraria lobata with hormone replacement therapy in treating the adverse health consequences of menopauseJean Woo
Department of Community and Family Medicine, The Chinese University of Hong Kong, Hong Kong
Menopause 10:352-61. 2003..The scientific basis for its action may be its action as a phytoestrogen...
- Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levelsVito Chiantera
Department of Gynecology and Obstetrics, Fatebenefratelli Hospital, Naples, Italy
Menopause 10:286-91. 2003..To compare the long-term effects of oral and transdermal hormone replacement therapy (HRT) on serum homocysteine levels in postmenopausal women...
- Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogensJ A Simon
Women's Health Research Center, Laurel, Maryland, USA
Menopause 8:321-7. 2001..The potential for long-term treatment compliance based on better bleeding control may optimize the opportunity to prevent osteoporosis as well as other associated health benefits...
- Hormone replacement therapy can augment vascular relaxation in post-menopausal women with type 2 diabetesM Perera
Department of Obstetrics and Gynaecology, University of Glasgow, G3 8SJ, UK
Hum Reprod 17:497-502. 2002..Observational studies have suggested that estrogens may provide cardioprotection by regulating endothelial nitric oxide synthase...
- Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trialMark A Hlatky
Stanford University School of Medicine, HRP Redwood Bldg, Room 150, Stanford, CA 94305 5405, USA
JAMA 287:591-7. 2002..Postmenopausal hormone therapy is commonly used by women for disease prevention, but its effects on quality of life have not been well documented...
- Effects of hormone replacement therapy on serum angiotensin-converting enzyme activity and plasma bradykinin in postmenopausal women according to angiotensin-converting enzyme-genotypeHiroyuki Sumino
Second Department of Internal Medicine, Gunma University School of Medicine, Showa machi, Maebashi, Japan
Hypertens Res 26:53-8. 2003..01, p < 0.01, and p < 0.01, respectively). These results suggest that the increased plasma bradykinin of PMW by HRT might not be induced solely by the reduction in serum ACE activity...
- Effects of tibolone and conventional hormone replacement therapies on arterial and hepatic cholesterol accumulation and on circulating endothelin-1, vascular cell adhesion molecule-1, and E-selectin in surgically menopausal monkeysThomas C Register
Comparative Medicine Clinical Research Center, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
Menopause 9:411-21. 2002....
- Discussing breast cancer and hormone replacement therapy with womenPelin Batur
Department of General Internal Medicine, Gault Women s Health and Breast Pavilion, The Cleveland Clinic Foundation, Ohio 44195, USA
Cleve Clin J Med 69:838, 840, 843-4 passim. 2002..We discuss limitations of the study, questions that remain, and how to discuss the study with women at average risk and high risk for breast cancer...
- Hormone replacement therapy does not affect plasma homocysteine in postmenopausal women with coronary artery disease. Free tissue factor pathway inhibitor antigen, a circulating anticoagulant, is related to plasma homocysteineIngrid Os
Department of Internal Medicine, Ulleval University Hospital, Oslo, Norway
Cardiology 98:6-12. 2002....
- [Tibolone]Christian Jamin
Service de gynécologie obstétrique CHU Bichat, 46, rue Henri Huchard 75018 Paris
Presse Med 31:1314-22. 2002..Certain tissues (liver, endometrium) may metabolize the 3 beta ol derivative into the delta 4 isomer with progestagenic and androgenic activity. The metabolism of the product in other tissues such as the breast and brain is unknown...
- Effects of low dose hormone replacement therapy on markers of inflammation in postmenopausal womenAssen Goudev
Department of Internal Medicine 2, Preventive Cardiology Clinic, Medical University Sofia, 1 G Sofiiski St, 1431 Sofia, Bulgaria
Maturitas 43:49-53. 2002..The effect of hormone replacement therapy (HRT) on these inflammatory markers is not uniform. In the presented study the effect of a low-dose HRT preparation, on sCAM, CRP and SAA in healthy postmenopausal women was evaluated...
- Impact of different hormone replacement therapy regimens on the size of myoma uteri in postmenopausal period: tibolone versus transdermal hormonal replacement systemT Simsek
Department of Obstetrics and Gynecology, Akdeniz University School of Medicine, Antalya, Turkey
Maturitas 42:243-6. 2002..To assess the effect of different hormone replacement therapy regimens on myoma uteri in postmenopausal period...
- Failure of estrogen plus progestin therapy for preventionSuzanne W Fletcher
JAMA 288:366-8. 2002
- Combination therapy of low-dose medroxyprogesterone acetate and oral estrogen does not affect endothelial function in the forearms of postmenopausal womenMitsuhiro Sanada
Department of Obstetrics and Gynecology, Faculty of Medicine, Hiroshima University, Hiroshima, Japan
Menopause 9:360-6. 2002..We investigated whether low-dose medroxyprogesterone acetate (MPA) combined with oral estrogen had adverse effects on endothelial function compared with oral estrogen alone in postmenopausal women with mild hypercholesterolemia...
- National differences in lipid response to postmenopausal hormone replacement therapyVarpu Ranta
Department of Obstetrics and Gynecology, Institute of Clinical Research, Helsinki University Central Hospital PB 140, 00029 Helsinki, Finland
Maturitas 42:259-65. 2002..To compare the response of serum lipids and lipoproteins to the transdermal hormone replacement therapy (HRT) in five European countries...
- Use of combination hormone replacement therapy in light of recent data from the Women's Health InitiativeAndrew M Kaunitz
University of Florida Health Science Center Jacksonville, USA
Medscape Womens Health 7:8. 2002
- Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrationsSven O Skouby
Department of Obstetrics and Gynecology, Frederiksberg Hospital, University of Copenhagen, Denmark
Am J Obstet Gynecol 186:969-77. 2002..Our purpose was to assess the effect of hormone replacement therapy (HRT) on C-reactive protein blood concentrations with special reference to the progestin component...
- Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese womenK S Tsai
Department of Laboratory Medicine, National Taiwan University Hospital and Medical College, Taipei, ROC
Osteoporos Int 12:1020-5. 2001..05). We conclude that in healthy, postmenopausal Taiwanese women, RLX 60 mg given daily has favorable results in BMD, bone turnover and serum lipids, although the dosage we used showed a potency less than that of conventional CCEP...
- The Women's Health Initiative estrogen plus progestin trial: the study and how it changes our practiceSusan L Hendrix
Wayne State University School of Medicine, Detroit, Mich, USA
J Am Osteopath Assoc 103:S3-5. 2003
- The effects of hormonal therapy on aortic stiffness and left ventricular diastolic functionSevket Gorgulu
Siyami Ersek Thoracic and Cardiovascular Surgery Center, Cardiology Department, Istanbul, Turkey
Acta Cardiol 58:1-8. 2003..The main objective of this study is to investigate the effects of oestrogen replacement therapy (ERT) and hormone replacement therapy (HRT) on aortic stiffness and on the left ventricular diastolic function, including tissue Doppler...
- Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic responseT Raudaskoski
Department of Obstetrics and Gynaecology, Oulu University Hospital, Finland
BJOG 109:136-44. 2002....
- [WHI study on the attention of menopause in Spain: significance of its results]Santiago Palacios
Instituto Palacios Antonio Acuña, 9 Local 28009 Madrid España
Med Clin (Barc) 120:146-7. 2003
- Effect of hormonal replacement therapy on C-reactive protein and cell-adhesion molecules in postmenopausal womenStefania Lamon-Fava
Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts 02111, USA
Am J Cardiol 91:252-4. 2003
- Postmenopausal hormone therapy and change in mammographic densityGail A Greendale
Division of Geriatric Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
J Natl Cancer Inst 95:30-7. 2003..Mammographic density is an independent risk factor for breast cancer. Postmenopausal hormone use is associated with an increase in mammographic density, but the magnitude of the density increase is unknown...
- Oral 17beta-estradiol (1 mg) continuously combined with dydrogesterone improves the serum lipid profile of postmenopausal womenBruno Pornel
Brussels Menopause Center, Brussels, Belgium
Menopause 9:171-8. 2002..To investigate the effects of 1 mg 17beta-estradiol continuously combined with 2.5, 5, 10, or 20 mg dydrogesterone on the serum lipid profile of postmenopausal women...
- Autonomic and cardiovascular function in postmenopausal women: the effects of estrogen versus combination therapyNoha H Farag
Department of Psychiatry, University of California, San Diego, UCSD Medical Center, 92103 0804, USA
Am J Obstet Gynecol 186:954-61. 2002..This study examined the effects of oral estrogen (ERT) alone versus oral estrogen/medroxyprogesterone acetate (HRT) therapy on cardiovascular function, as controlled by the autonomic nervous system...
- Six months of hormone replacement therapy does not influence muscle strength in postmenopausal womenEva L Ribom
Department of Surgical Sciences, Section of Orthopaedics, University of Uppsala, Uppsala, Sweden
Maturitas 42:225-31. 2002..This has been attributed to increased muscle strength by HRT. This study was designed to evaluate the effect of 6 months of HRT on muscle strength in postmenopausal women...
- Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trialJane A Cauley
Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15261, USA
JAMA 290:1729-38. 2003..In the Women's Health Initiative trial of estrogen-plus-progestin therapy, women assigned to active treatment had fewer fractures...
- Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal womenFiliz Cayan
Department of Obstetrics and Gynecology, University of Mersin School of Medicine, Mersin, Turkey
J Sex Med 5:132-8. 2008..Sexual dysfunction is more prevalent in postmenopausal women...
- The effects of synthetic 19-norprogestins on osteoblastic cell function are mediated by their non-phenolic reduced metabolitesJuana Enríquez
Department of Reproductive Biology, Instituto Nacional de Ciencias Médicas y Nutrición S Zubirán INCMNSZ, Mexico City 14000, Mexico
J Endocrinol 193:493-504. 2007....
- Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label studyG Samsioe
Department of Obstetrics and Gynecology, Lund University Hospital, Lund, Sweden
Climacteric 9:368-79. 2006..To establish whether transdermal continuous hormone replacement therapy (HRT) with estrogen/progestogen provides adequate long-term endometrial protection in postmenopausal women over a period of 96 weeks...
- alpha-Tocopherol and beta-carotene serum levels in post-menopausal women treated with transdermal estradiol and oral medroxyprogesterone acetateC Clemente
Laboratory of Biochemistry, IRCCS S. De Bellis, Castellana G, Italy
Horm Metab Res 28:558-61. 1996..These preliminary findings suggest that HRT can preserve the content of alpha-tocopherol and beta-carotene in LDL particles and keep the LDL in a reduced antioxidant state...
- Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research GroupS Hulley
University of California, San Francisco 94143, USA
JAMA 280:605-13. 1998..However, given the favorable pattern of CHD events after several years of therapy, it could be appropriate for women already receiving this treatment to continue...
- Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal womenRobert Lindsay
Internal Medicine, Helen Hayes Hospital, Rte 9W, West Haverstraw, NY 10993, USA
JAMA 287:2668-76. 2002..This lower-dose therapy's protection against loss of bone mineral density (BMD) associated with menopause has not been thoroughly investigated...
- Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal womenSee Kwok
Barlow Medical Centre, 8 Barlow Moor Road, Manchester M20 6TR, UK
Maturitas 53:439-46. 2006....
- Progestins and estrogens and Alzheimer's diseaseHideo Honjo
Department of Gynecology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kawaramachi, Hirokoji, Kamigyo ku, Kyoto 602 8566, Japan
J Steroid Biochem Mol Biol 93:305-8. 2005..like E2. More investigations about progestins and estrogens and AD should be done...
- [Risk and benefits of hormone replacement therapy by postmenopausal women. WHI-Study]V Heinemann
Medizinische Klinik II, Grosshadern, Klinikum der Ludwig Maximilians Universität München
Internist (Berl) 44:896-8. 2003
- Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factorsF P Chen
Department of Obstetrics and Gynecology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan, Republic of China
Menopause 8:347-52. 2001..However, it needs to be considered that there is an increased risk of venous thrombotic events in the first year of treatment...
- Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) TrialGiske Ursin
Department of Preventive Medicine, Norris Comprehensive Cancer Center, Room 4407, USC Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90089, USA
J Clin Oncol 22:2842-8. 2004..We determined whether increases in serum estrone as a function of treatment predict increases in mammographic percent density...
- Nondaily hormonal contraception: establishing a fit between product characteristics and patient preferencesJeffrey P Levine
Departments of Family Medicine and Obstetrics, Gynecology and Reproductive Sciences, UMDNJ Robert Wood Johnson Medical School, 1 RWJ Place, CN19, New Brunswick, NJ 08903 0019, USA
J Fam Pract 53:904-13. 2004
- Consortium for the Assessment of Research on Progestins and Estrogens (CARPE) Fort Worth, Texas August 1-3, 2003James W Simpkins
J Womens Health (Larchmt) 13:1165-8. 2004
- A clinician's review of the WHI-related literatureLeon Speroff
Department of Obstetrics and Gynecology, Oregon Health Sciences University Portland, Oregon 97239, USA
Int J Fertil Womens Med 49:252-67. 2004....
- The effects of estrogen therapy and estrogen combined with different androgenic progestins on carbohydrate and lipid metabolism in overweight-obese younger postmenopausal womenBerfu Demir
Department of Obstetrics and Gynecology, Ministry of Health Ankara Etlik Maternity and Women s Health Teaching Research Hospital, Ankara, Turkey
Gynecol Endocrinol 24:347-53. 2008..Additionally, the relationship between testosterone and insulin resistance was assessed...
- Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferationM H Jeng
Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison 53792
Cancer Res 52:6539-46. 1992..Our results may help to explain the conflicting evidence linking OC and breast cancer risk. A rigorous evaluation of the "total" estrogenic potential of OC might produce a better correlation with breast cancer risk...
- Progestin regulation of vascular endothelial growth factor in human breast cancer cellsS M Hyder
Department of Integrative Biology, Pharmacology and Physiology, University of Texas Health Sciences Center Houston, 77225, USA
Cancer Res 58:392-5. 1998....
- Classification and pharmacology of progestinsAdolf E Schindler
Institut für Medizinische Forschung und Fortbildung, Universitatsklinikum, Hufelandstr 55, Essen 45147, Germany
Maturitas 46:S7-S16. 2003..Besides the progestogenic effect, which is in common for all progestins, there is a wide range of biological effects, which are different for the various progestins and have to be taken into account, when medical treatment is considered...
- Classification and pharmacology of progestinsAdolf E Schindler
, , Hufelandstr 55, Essen 45147, Germany
Maturitas 61:171-80. 2008..Besides the progestogenic effect, which is in common for all progestins, there is a wide range of biological effects, which are different for the various progestins and have to be taken into account, when medical treatment is considered...
- Glucocorticoid-recognizing and -effector sites in rat liver plasma membrane. Kinetics of corticosterone uptake by isolated membrane vesicles. III. Specificity and stereospecificityC Lackner
Department of Internal Medicine, University of Graz, Austria
J Steroid Biochem Mol Biol 64:69-82. 1998..The GC importer seems to be an additional link in the chain of steroid signal transduction and may be functionally involved in the action of natural GC-agonists and GC-antagonists...
- The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?Kent Holtorf
Holtorf Medical Group, Inc, Torrance, CA 90505, USA
Postgrad Med 121:73-85. 2009..Yet according to the US Food and Drug Administration and The Endocrine Society, there is little or no evidence to support claims that bioidentical hormones are safer or more effective...
- The use of newer progestins for contraceptionRegine Sitruk-Ware
Population Council and Rockefeller University, New York, NY 10065, USA
Contraception 82:410-7. 2010..Risks and benefits of the new progestins depend upon the type of molecular structure, the type of estrogen associated in a combination and the route of administration...
- Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostateC Labrie
Medical Research Council Group in Molecular Endocrinology, Laval University Medical Center, Quebec, Canada
Mol Cell Endocrinol 68:169-79. 1990..Consequently, as indicated by this sensitive and androgen-specific in vivo rat model, such compounds are not recommended for the treatment of conditions requiring an optimal blockade of androgens, especially prostate cancer...
- Inhibition of rat ovarian 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD), 17 alpha-hydroxylase and 17,20 lyase by progestins and danazolS Arakawa
Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo, Japan
Endocrinol Jpn 36:387-94. 1989..3 microM) and danazol (168 microM) inhibited 17 alpha-hydroxylase. All the steroids inhibited 17,20 lyase, and the inhibition by desogestrel (Ki = 0.70 microM), danazol (0.80 microM), and gestrinone (30 microM) was particularly marked...
- Occurrence of androgens and progestogens in wastewater treatment plants and receiving river waters: comparison to estrogensHong Chang
Laboratory for Earth Surface Processes, College of Urban and Environmental Sciences, Peking University, Beijing, China
Water Res 45:732-40. 2011..Different profiles of progestogens in the receiving rivers and WWTP effluents were observed, which could be explained by the discharge of a mixture of treated and untreated wastewater into the receiving rivers...
- Reproductive responses in fathead minnow and Japanese medaka following exposure to a synthetic progestin, NorethindronePeter Paulos
Department of Biology, University of North Texas, Denton, TX 76203, USA
Aquat Toxicol 99:256-62. 2010..Collectively, these data indicate that further investigation of reproductive responses associated with synthetic progestins is warranted...
- Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in miceM Plante
Medical Research Council Group in Molecular Endocrinology, Laval University Medical Center, Quebec, Canada
J Steroid Biochem 31:61-4. 1988....
- Selective effect of chlormadinone acetate on brain allopregnanolone and opioids contentNicola Pluchino
Department of Reproductive Medicine and Child Development, Division of Gynecology and Obstetrics, University of Pisa, 56100 Pisa, Italy
Contraception 80:53-62. 2009....
- Cell surface-binding sites for progesterone mediate calcium uptake in human spermP F Blackmore
Department of Pharmacology, Eastern Virginia Medical School, Norfolk 23501
J Biol Chem 266:18655-9. 1991..It is proposed that a distinct nongenomic cell surface receptor for progesterone exists in human sperm...
- Inhibitory effect of synthetic progestins, 4-MA and cyanoketone on human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase activityM Takahashi
MRC Group in Molecular Endocrinology, CHUL Research Centre, Quebec, Canada
J Steroid Biochem Mol Biol 37:231-6. 1990..5, 1.7 and 2.5 microM, respectively...
- Structure-activity relationships of synthetic progestins in a yeast-based in vitro androgen bioassayL McRobb
Heart Research Institute, Sydney, NSW 2050, Australia
J Steroid Biochem Mol Biol 110:39-47. 2008..By contrast, modern progestins such as progesterone, 17alpha-hydroxyprogesterone and 19-norprogesterone derivatives had minimal androgenic bioactivity and pose low risk...
- Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopauseH Marret
centre hospitalo universitaire de Tours, Hopital Bretonneau, Service de Gynecologie, Tours 37044 cédex 1, France
Eur J Obstet Gynecol Reprod Biol 152:133-7. 2010..The prevalence of abnormal uterine bleeding (AUB) is estimated at 11-13% in the general population and increases with age, reaching 24% in those aged 36-40 years...
- Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actionsO Heikinheimo
Jones Institute for Reproductive Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk 23507, USA
Contraception 53:55-64. 1996..We conclude that when inhibiting ovulation, RU486 does not act as a progestin agonist, but rather, functions through a hypothalamic mechanism(s), which might be unique to RU486 as a progesterone antagonist...
- Progestagens and mammary gland development: differentiation versus carcinogenesisI H Russo
Department of Pathology, Fox Chase Cancer Center, Philadelphia
Acta Endocrinol (Copenh) 125:7-12. 1991..DNA labeling index was significantly reduced in terminal ducts and alveolar buds by all hormones at all doses, except PL.(ABSTRACT TRUNCATED AT 250 WORDS)..
- Luteolytic effect of the antiprogestin and antiglucocorticoid agent RU486 in ratsS Arakawa
Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo, Japan
J Steroid Biochem 36:479-83. 1990..These results show that RU486 decreases progesterone synthesis in cultured ovarian cells. A part of the mechanism may involve an inhibition of CSCC...
- Progestins in breast cancer treatment. A reviewS Lundgren
Department of Oncology, Regional and University Hospital of Trondheim, Norway
Acta Oncol 31:709-22. 1992..Further studies on the influence of progestin on different receptors and growth factors are warranted. To determine the most effective clinical dose of the two progestins, studies with increasing therapeutic doses are needed...
- Mechanisms of cyclin-dependent kinase inactivation by progestinsE A Musgrove
Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, Sydney, New South Wales, Australia
Mol Cell Biol 18:1812-25. 1998..Thus, decreased cyclin expression and consequent increased CDK inhibitor association are likely to mediate the decreases in CDK activity accompanying progestin-mediated growth inhibition...
- Effects of synthetic progestagens on the mRNA expression of androgen receptor, progesterone receptor, oestrogen receptor alpha and beta, insulin-like growth factor-1 (IGF-1) and IGF-1 receptor in heifer tissuesM W Pfaffl
Institute of Physiology, Centre of Life and Food Sciences, Technical University of Munich, Germany
J Vet Med A Physiol Pathol Clin Med 49:57-64. 2002..ERalpha in liver and neck muscle showed a trend of increasing expression...
- Induction of micronuclei and of enzyme-altered foci in the liver of female rats exposed to progesterone and three synthetic progestinsA Martelli
Department of Internal Medicine, Division of Clinical Pharmacology and Toxicology, University of Genoa, I 16132, Genoa, Italy
Mutat Res 419:33-41. 1998..Considered together with previous findings, these results suggest that NE might be biotransformed in the liver into reactive species and thus behave as a weak genotoxic agent...
- Effect of an oral contraceptive with chlormadinone acetate on depressive mood : analysis of data from four observational studiesJohannes C Huber
Department of Gynaecology and Obstetrics, Division of Gynaecological Endocrinology and Reproductive Medicine, University of Vienna, Vienna, Austria
Clin Drug Investig 28:783-91. 2008..The aim of these studies was to describe the clinical effects of CMA in combination with ethinylestradiol on depressive mood symptoms...
- A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesteroneLee P Shulman
Department of Obstetrics and Gynecology, Division of Reproductive Genetics and Graduate Program in Genetic Counseling, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
J Womens Health (Larchmt) 15:584-90. 2006....
- ContraceptionG R Huggins
Francis Scott Key Medical Center, Baltimore, Maryland
Curr Opin Obstet Gynecol 2:291-5. 1990..However, the risk was overstated earlier. Women who have only 1 sexual partner in their lifetime had no significant risk of tubal infertility. "lost" IUDs continue to be a problem...
- Reproductive cycles and contraception of black lemurs (Eulemur macaco macaco) with depot medroxyprogesterone acetate during the breeding seasonCheryl S Asa
Saint Louis Zoo, St Louis, Missouri
Zoo Biol 26:289-98. 2007..Zoo Biol 26:289-298, 2007. (c) 2007 Wiley-Liss, Inc...
- Pharmacological profile of progestinsRegine Sitruk Ware
Rockefeller University and Population Council, New York, NY, USA
Maturitas 61:151-7. 2008..The progestins available for therapy exhibit profound differences according to their structure or metabolites and it is inappropriate to consider the various effects of the old and new molecules as class-effects...
- Pharmacological profile of progestinsRegine Sitruk-Ware
Rockefeller University and Population Council, New York, NY, USA
Maturitas 47:277-83. 2004..The progestins available for therapy exhibit profound differences according to their structure or metabolites and it is inappropriate to consider the various effects of the old and new molecules as class-effects...
- Steroid regulation of prostaglandin dehydrogenase activity and expression in human term placenta and chorio-decidua in relation to laborF A Patel
Department of Physiology, University of Toronto, Ontario, Canada
J Clin Endocrinol Metab 84:291-9. 1999..We conclude that cortisol inhibits PGDH activity and expression and that progestagens increase PGDH activity in human chorion and placenta...
- [New gestagens--advantages and disadvantages]H Kuhl
Zentrum der Frauenheilkunde und Geburtshilfe, Klinikum der J W Goethe Universität Frankfurt am Main
Ther Umsch 58:527-33. 2001..According to their different hormonal profiles and activities, the various available progestogens allow the choice of preparations which are best suitable for the individual woman for contraception or hormone replacement therapy...
- Progesterone receptor immunoreactivity differs in the uterus of pseudopregnant and medroxyprogesterone acetate-treated rabbitsSantiago R Anzaldúa Arce
Facultad de Medicina Veterinaria y Zootecnia, Departamento de Morfologia, Universidad Nacional Autonoma de Mexico, Ciudad Universitaria, Coyoacan 04510, Mexico, D F, Mexico
Anim Reprod Sci 120:173-8. 2010..The present study indicated synthetic progestins have different mechanisms of receptor regulation than those of natural hormones and it should be taken into account in reproductive applications...
- Regulation of CD4+ T cell responses by a progesterone receptorGrant Hughes; Fiscal Year: 2013....
- Identification of novel phytoprogestins from hops and red cloverJoanna E Burdette; Fiscal Year: 2011..As women search for more potent alternative estrogens to satisfy the need for menopausal symptom alleviation, the chance for hyperplasia in the uterus increases and makes the characterization of novel phytoprogestins crucial. ..
- Oral contraceptive use by formulation and breast cancer risk by subtypeDIANA SM BUIST; Fiscal Year: 2010..This area of research is critical given the high frequency of OC use, heterogeneity of OC formulations, changes in OC formulations over time, and the morbidity and mortality associated with different breast cancer subtypes. ..
- Progestin Effects on Uterine Hemostatis &AngiogenesisCharles Lockwood; Fiscal Year: 2011..Moreover, a model will be established to test innovative LTPOC formulations that minimize uterine and endometrial vasoconstriction and ROS-generation, thus preventing abnormal bleeding to improve the acceptability of LTPOC therapies. ..
- Progesterone Treatment for Cocaine-Dependent WomenSuzette Evans; Fiscal Year: 2009..e., women who primarily use cocaine by other routes other than smoked). ..
- PRENATAL EXPOSURE TO HORMONES IN MAN AND ANIMALJUNE REINISCH; Fiscal Year: 1980....
- DEVELOPMENT OF A NOVEL ORAL PROGESTERONE DRUGROBIN FOLDESY; Fiscal Year: 1992..It is further expected that an oral formulation would be more acceptable to patients than rectal, parenteral, or vaginal progesterone formulations...
- Progesterone-mediated protection against ovarian cancerShuk Mei Ho; Fiscal Year: 2009..Results from this proposal have the potential to generate new strategies for the prevention and treatment of OCa. ..
- Estrogen Receptor Variants,HDL, and AtherosclerosisDavid Herrington; Fiscal Year: 2005....
- ESTROGEN, INFLAMMATION AND ATHEROSCLEROSISDavid Herrington; Fiscal Year: 2001....
- Estrogen Receptor Variance and CHD Risk in HERSDavid Herrington; Fiscal Year: 2004..In addition, this information could lead to fundamentally important new knowledge about mechanisms of estrogen action, regulation of HDL cholesterol, and pathogenesis of CHD. ..
- Machine Learning to Identify Complex Interactions in Genome-Wide Association DataDavid Herrington; Fiscal Year: 2009..Determining specific genetic and/or environmental factors that influence a person's risk of disease may help doctors reduce risk for disease and reveal new treatments for disease. (End of Abstract) ..
- Thrombosis Gene Polymorphisms and Early CHD Risk in HERSDavid Herrington; Fiscal Year: 2004....
- Outcomes of Sleep Disorders in Older Men - PittsburghJane Cauley; Fiscal Year: 2007..We will also supplement the bank of MrOS specimens to allow for testing of future hypotheses concerning the role of sleep in the development of age-related diseases and conditions. [unreadable] [unreadable]..
- PROGESTERONE, TBI AND CNS REPAIR IN MATURE & AGED RATS.Donald Stein; Fiscal Year: 2008..unreadable] [unreadable]..
- Graylyn Conference on Women's Cognitive HealthSally Shumaker; Fiscal Year: 2007..5. Facilitate development of novel approaches to disease prevention, progression and treatment, which can then be tested by new research. [unreadable] [unreadable] [unreadable]..
- Mammographic density, genes and estradiol/norethisterone based EPT regimensGiske Ursin; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- BREAST CANCER PATTERNS OF CARE AND MORBIDITYSandra Norman; Fiscal Year: 2007..Preliminary data from the parent study suggest that only longer follow-up can capture the interplay of time-dependent risks, ongoing treatment, and patient characterisitics that occur over a longer period of time. ..
- PDE3 Inhibitors: Selective Blockers of Oocyte MaturationJeffrey Jensen; Fiscal Year: 2007..This approach is expected to provide a foundation for future Phase 1 trials of PDE3 inhibitors in humans. ..
- ROLE OF STROMA IN MAMMARY GLAND CELL PROLIFERATIONSANDRA HASLAM; Fiscal Year: 2007..The long-term goal of this proposal is the delineation of the mechanisms of P-dependent growth regulation in the adult normal mammary gland that may lead to novel strategies for the prevention and treatment of breast cancer. ..
- Stress, Sleep and Emerging CVD Risk FactorsKaren Matthews; Fiscal Year: 2007..The study will provide novel data testing the relationships of daytime stressful events, SDB, and other nocturnal physiological measures with the emerging risk factors and subclinical CVD measured in HeartSCORE. [unreadable] [unreadable]..
- Effects of Perinatal Depression on PTD and LBWKimberly Yonkers; Fiscal Year: 2008..Further, if we determine antidepressants increase the risk of adverse perinatal outcomes, treatment with psychotherapy rather than antidepressants should be considered when recommending therapeutic options. [unreadable] [unreadable]..
- Psychosocial Res. to Improve Drug Treatment in PregnancyKimberly Yonkers; Fiscal Year: 2008..unreadable] [unreadable] [unreadable] [unreadable]..
- Phase III Study of Donepezil in the Irradiated BrainStephen R Rapp; Fiscal Year: 2010..If successful the study will offer physicians a treatment for radiation-induced cognitive impairment which also may improve mood and quality of life. ..
- Prophylactic Ibuprofen: Effect on IUD Continuation RatesDavid Hubacher; Fiscal Year: 2003..In the US, ibuprofen may help spur renewed interest in the most cost effective and efficacious reversible contraceptive method available. ..
- A MECHANISTIC STUDY OF SKELETAL ACTIONS OF 1-34hPTHRobert Lindsay; Fiscal Year: 2009..abstract_text> ..
- Soy and Estrogen Interactions in the BreastJ Cline; Fiscal Year: 2009..The proposed work will provide a unique view of an otherwise inaccessible period of breast development in a primate model with high genetic and physiologic similarity to human beings. ..
- Determination of RDA for Vitamin D in Caucasian and African American WomenJohn Gallagher; Fiscal Year: 2009..The results from this study will also help in designing future larger clinical trials of the effect of vitamin D on falls and fractures. ..
- Estrogen and progestin crosstalk via binding of PR at estrogen response elementsSTEVEN NORDEEN; Fiscal Year: 2008..abstract_text> ..
- Oral Androgen Administration and Function in ManJOHN AMORY; Fiscal Year: 2008..Matsumoto M.D., Director, Clinical Research Unit VA-Puget Sound and Professor of Medicine, University of Washington School of Medicine will co-mentor this award. [unreadable] [unreadable]..
- Atherosclerosis Stage, Estrogen Receptors, and Vascular Responses to EstrogenTHOMAS COSTIN REGISTER; Fiscal Year: 2010....
- DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORSDavid Archer; Fiscal Year: 2006..If successful, DOX treatment could become an important adjuvant for treatment of this and possibly other inflammatory disorders effecting reproductive tract tissues. ..
- Control of menstrual bleeding disturbances in womenIan Fraser; Fiscal Year: 2006..This study aims to explore these possibilities in large scale clinical studies, scientific study of vascular and molecular changes in endometrium and with the exploration of molecular mechanisms in mice. ..
- CHLORHEXIDINE IRRIGATION TO PREVENT INFECTIONDwight Rouse; Fiscal Year: 2001....
- VASCULAR INTERACTION WITH AGE IN MYOCARDIAL INFARCTIONSteven Schulman; Fiscal Year: 2004..We anticipate that the study findings will suggest the use of new evaluation and therapeutic strategies, which will significantly decrease the age associated mortality and morbidity in post-infarction patients. ..
- Pregnancy Hormonal Profile/Biomarker Breast Cancer RiskAlan Arslan; Fiscal Year: 2004..Moreover, specific hormone(s) or its analogues responsible for protective effect of pregnancy against breast cancer could be used for development of novel strategies for primary chemoprevention of breast cancer. ..
- MIDCAREER AWARD IN PATIENT ORIENTED OBSTETRIC RESEARCHDwight Rouse; Fiscal Year: 2004..Finally, the effectiveness of an intervention (how it would perform under conditions of actual clinical practice) is an attribute that, in many situations, is as important as its efficacy (how it performs under ideal conditions). ..
- Biomarkers of Ovarian Cancer Risk: A Prospective StudyAlan Arslan; Fiscal Year: 2004....
- 9th annual Graylyn Conference: Women's Cognitive HealthSally Shumaker; Fiscal Year: 2003..5. Provide opportunities for students and junior faculty to participate in the process. 6. Facilitate development of novel approaches to disease prevention, progression and treatment, which can be tested. ..
- CANCER CHEMOPREVENTION--ROLE OF INFECTION/IMMUNITYCharles Loprinzi; Fiscal Year: 2003..abstract_text> ..
- Treating PMS/PMDD--Research versus Clinical RealityKimberly Yonkers; Fiscal Year: 2003....
- DETECTION AND TREATMENT OF POSTPARTUM DEPRESSIONKimberly Yonkers; Fiscal Year: 2003..abstract_text> ..
- Progestin Regulation of VEGF in Breast Cancer CellsSALMAN HYDER; Fiscal Year: 2005..abstract_text> ..
- PROGESTERONE AFTER TRAUMATIC BRAIN INJURYDonald Stein; Fiscal Year: 2005..Furthermore, the detailed assessment of progesterone's mechanisms of action will provide a foundation for the intelligent design of artificial therapeutic pharmaceuticals. ..
- Chaperones, chromatin, and transcriptional control by PRSTEVEN NORDEEN; Fiscal Year: 2006..Together, the studies proposed will provide fundamental knowledge that will advance our understanding of steroid receptor action in human health and disease. ..
- 10th Annual Graylyn Conference on Women's Cognitive HealthSally Shumaker; Fiscal Year: 2005..4. Provide opportunities for students and junior faculty to participate in the process. 5. Facilitate development of novel approaches to disease prevention, progression and treatment, which can then be tested by new research. ..
- ECONOMIC OUTCOMES OF TREATMENT STRATEGIES IN BAR1-2Mark Hlatky; Fiscal Year: 2006..The investigators further expect that this collaborative effort will translate into a new practical clinical paradigm that will be used for treatment of Type II diabetic patients. ..
- Hormones and Biomarkers Predicting Stroke in WomenSylvia Wassertheil Smoller; Fiscal Year: 2005..abstract_text> ..
- STUDY OF OSTEOPOROTIC FRACTURESJane Cauley; Fiscal Year: 2005....
- Depo-provera & BMD: Continuing ObservationsM Clark; Fiscal Year: 2005..The longitudinal design will be continued, maintaining all methods and protocols employed in the parent study. ..
- Serum Vitamin D, Genetic Polymorphisms & Ovarian CancerAlan Arslan; Fiscal Year: 2005..abstract_text> ..
- MOLECULAR MECHANISMS OF GLUCOCORTICOID HORMONE ACTIONSTEVEN NORDEEN; Fiscal Year: 2004..Together these studies will make significant contributions to our understanding of hormone action. ..
- Ventricular Size and Valve Calcification Measures by CTMatthew J Budoff; Fiscal Year: 2010..abstract_text> ..
- The effects of progesterone and its metabolites on TBIDonald Stein; Fiscal Year: 2004..abstract_text> ..
- Pittsburgh Mind-Body Center-IIKaren Matthews; Fiscal Year: 2008..Support-in-kind from the host institutions will enable us to leverage the funds provided by the RFA to expand Center activities that would not otherwise be possible. ..
- Estradiol, Cytokines & Bone Turnover--Effects on FractureJane Cauley; Fiscal Year: 2007..Improved understanding of the biological mechanisms for these associations could lead to the development and testing of preventive intervention. ..
- Recovery of functional p53 as a therapeutic approach for breast cancerSALMAN HYDER; Fiscal Year: 2008..Furthermore, we contend that the research will provide critical data relevant to minimizing breast cancer risk and metastasis in post-menopausal women and other women exposed to exogenous progestins. ..
- Effects of Dietary Soy on Biomarkers in Prostate CancerJ Cline; Fiscal Year: 2004..abstract_text> ..
- 6th International Symposium on OsteoporosisRobert Lindsay; Fiscal Year: 2005..abstract_text> ..
- ANXIETY, DISINHIBITION, AND RISK FOR DRUG ABUSEKimberly Yonkers; Fiscal Year: 2003..phenotypic indices of vulnerability using combinations of clinical and psychophysiological measures. ..